Intervacc AB (publ) (STO:IVACC)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.740
+0.066 (9.79%)
Mar 9, 2026, 5:29 PM CET
-26.00%
Market Cap 229.71M
Revenue (ttm) 20.09M
Net Income (ttm) -80.82M
Shares Out 340.81M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,065,006
Average Volume 714,520
Open 0.699
Previous Close 0.674
Day's Range 0.650 - 0.775
52-Week Range 0.572 - 1.352
Beta 0.37
RSI 40.85
Earnings Date Feb 16, 2026

About Intervacc AB

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company’s product pipeline includes Stangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against streptococcus suis for the treatment of weaned piglets; and INV412, a multi-component vaccine to protect against several bacteria which cause mastitis for treating cows. It also engages in marketing and distribution of veterinary products in the Nordic markets, which includes vaccines and pharmaceuticals for swine, horses, cattle, and... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1983
Employees 15
Stock Exchange Nasdaq Stockholm
Ticker Symbol IVACC
Full Company Profile

Financial Performance

In 2025, Intervacc AB's revenue was 20.09 million, an increase of 70.42% compared to the previous year's 11.79 million. Losses were -80.82 million, 7.02% more than in 2024.

Financial Statements

News

Earnings To Watch: Intervacc AB (OSTO:IVACC) Reports Q4 2025 Result

Earnings To Watch: Intervacc AB (OSTO:IVACC) Reports Q4 2025 Result

24 days ago - GuruFocus

What To Expect From Intervacc AB (OSTO:IVACC) Q3 2025 Earnings

What To Expect From Intervacc AB (OSTO:IVACC) Q3 2025 Earnings

3 months ago - GuruFocus